Lurasidone: A new treatment option for bipolar depression— A review

Innovations in Clinical Neuroscience

Volumn 12, Issue 1-2, 2015, Pages 21-23

  Bawa, Radhika ^a   Scarff, Jonathan R ^b  

^a CITY UNIVERSITY OF NEW YORK   (United States)

^b Veterans Affairs Outpatient Clinic   (United States)

Author keywords

Antipsychotic; Bipolar disorder; Depression; Lurasidone

Indexed keywords

ADRENERGIC RECEPTOR; CHOLINERGIC RECEPTOR; CYTOCHROME P450 3A4; FLUOXETINE PLUS OLANZAPINE; HISTAMINE RECEPTOR; LITHIUM; LURASIDONE; QUETIAPINE; VALPROIC ACID;

AKATHISIA; BIPOLAR DEPRESSION; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA AND VOMITING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOMNOLENCE; TREMOR;

EID: 84938083174     PISSN: 21588333     EISSN: 21588341     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Press Inc.; 2013
2. Yatham L, Kusumakar V, Parikh S, et al. Bipolar depression: treatment options. Can J Psychiatry. 1997;42(2):87S.
3. Sagman D, Tohen M. Comorbidity in bipolar disorder. Psychiatr Times. 2009;26(4):1–9
4. Van Winkel R, De Hert M, Van Eyck D, et al. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder. Bipolar Dis. 2008;10(2):342–348
5. Vancampfort D, Vansteelandt K, Correll C, et al. Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry. 2013;170(3):265–274
6. Woo YS, Wang HR, Bahk WM. Lurasidone as a potential therapy for bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1521–1529
7. Belmaker R. Lurasidone and bipolar disorder. Am J Psychiatry. 2014;171:131–133
8. Srivastava S, Ketter T. Clinical relevance of treatments for acute bipolar disorder: balancing therapeutic and adverse effects. Clin Ther. 2011;33(12):B40–48
9. Cates, LN, Roberts AJ, Huitron- Resendiz S, Hedlund PB. Effects of lurasidone in behavioral models of depression. Role of the 5-HT7 receptor subtype. Neuropharmacology. 2013;70:211–217
10. Seager M, Barth V, Phebus L, et al. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology. 2005;181(1):126–133
11. Sunovion. Latuda (lurasidone hydrochloride) package insert. Sunovion Pharmaceuticals Inc. Marlborough, Massachusetts. July 2013
12. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract. 2011;65(2):189–210
13. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5- hydroxytryptamine7 (5-HT7) and 5-HT1A receptor activity. J Pharmacol Exp Ther. 2010;334(1):171–181
14. Yatham L, Goldstein J, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66(Suppl 5):40–48
15. Kinney G, Taber M, Gribkoff V. The augmentation hypothesis for improvement of antidepressant therapy. Mol Neurobiol. 2000;21(3):137–152
16. Yatham L, Liddle P, Shiah S, et al. PET study of [18F] 6-fluoro-L-dopa uptake in neuroleptic-and moodstabilizer- naive first-episode nonpsychotic mania: effects of treatment with divalproex sodium. Am J Psychiatry. 2002;159(5):768–774
17. Cousins D, Butts K, Young A. The role of dopamine in bipolar disorder. Bipolar Dis. 2009;11(8):787–806
18. Kane J. Lurasidone: a clinical overview. J Clin Psychiatry. 2010;72:24–28
19. Tarazi F, Zhang K, Baldessarini R. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: implications for antipsychotic drug treatment. J Pharmacol Exp Ther. 2001;297(2):711–717
20. Gosh R, Gupta R, Bhatia MS, et al. Lurasidone: a novel drug. Del Psychiatry J. 2013;16(1):177–181
21. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–168
22. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389
23. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res. 1997;73(3):159–171
24. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, doubleblind, placebo-controlled study. Am J Psychiatry. 2014;171(2):169–177
25. Citrome L, Ketter T, Cucchiaro J, et al. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and likelihood to be helped or harmed. J Affect Disord. 2014;155:20–27.